Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.01 CAD | 0.00% | +9.85% | +173.64% |
05:31pm | Cardiol Therapeutics Says Phase II ARCHER Trial Presented at World Congress on Acute Heart Failure | MT |
04-22 | HC Wainwright Starts Cardiol Therapeutics With Buy Rating, $9 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+173.64% | 150M | |
+29.38% | 48.16B | |
-1.02% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+10.17% | 25.59B | |
-23.19% | 18.96B | |
+8.32% | 12.92B | |
+28.77% | 12.03B | |
-1.93% | 11.77B |
- Stock Market
- Equities
- CRDL Stock
- News Cardiol Therapeutics Inc.
- Cardiol Therapeutics Enrolls Over 50% of Patients for Phase II ARCHER Trial in Acute Myocarditis